

## COVID-19 Vaccination in Cancer Patients

Attapon Cheepsattayakorn<sup>1,2\*</sup>, Ruangrong Cheepsattayakorn<sup>3</sup> and Porntep Siriwanarangsun<sup>1</sup>

<sup>1</sup>Faculty of Medicine, Western University, Pathumtani Province, Thailand

<sup>2</sup>10<sup>th</sup> Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand

<sup>3</sup>Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

\*Corresponding Author: Attapon Cheepsattayakorn, 10<sup>th</sup> Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: August 27, 2021

Published: September 08, 2021

© All rights are reserved by Attapon Cheepsattayakorn, et al.

In patients with cancer, SARS-CoV-2 (COVID-19) can contribute to increasing morbidity and mortality [1-3] and decreased survival was found in patients with hematological and intrathoracic malignancies, poor performance status, comorbidities, and increased age [3-5]. Patients with hematological malignancies who were treated with stem cell transplantation and anti-CD-20 antibody demonstrated lower rates of seroconversion, compared to COVID-19-infected-cancer patients [6,7]. Patients with hematological malignancies might have substantially compromised B-cell and T-cell responses [8]. These study results indicated that following COVID-19 vaccination, overall high seroconversion rates could be anticipated in cancer patients due to different mechanisms and degrees of immune suppression, such as cell therapies (particularly chimeric antigen receptor (CAR)-T cell), anti-CD-20 antibody (B-cell depleting) therapies, stem cell transplantation, immunosuppressive effects of corticosteroid treatment, and cytotoxic-chemotherapy-bone-marrow-suppressive effects in certain subgroups of cancer patients [9]. Currently, there are lacking data in cancer patients in protection following SARS-CoV-2 (COVID-19) infection, reinfection by various SARS-CoV-2 (COVID-19) variants, or COVID-19 vaccination although mucosal surface antigens (e.g. IgA and protective T-cell responses) might be similarly important in protection from natural SARS-CoV-2 (COVID-19) infection [10]. The association of carcinogenesis with genomic information encoding vaccines, particularly with very-transient-intracellular-presence-COVID-19-mRNA vaccines is likely very low [11]. Hypothetically, mRNA-vaccine-encapsulated-small liposomes and lipid

carriers may accumulate through the permeation retention and enhanced effect in tumor tissues [12,13]. The recommendation that have been suggested administering COVID-19 vaccines one to two weeks prior to a chemotherapy dose by many key-professional organizations has not been practical with COVID-19 administration schedules (for examples; two doses of mRNA-1273 (Moderna) are recommended to be given 28 days apart, whereas two doses of BNT162b2 (Pfizer/BioNTech) are given 21 days apart, efficacy > 94%), variable chemotherapeutic regimens, and limited COVID-19 vaccination slot availability, contributing to allowing the most rapid COVID-19 vaccination of these immunosuppressed cancer patients [14] and due to lacking COVID-19- vaccine safety and the information immunogenicity in the context of immune-system-stimulated immunotherapies (for examples; immune checkpoint inhibitor (ICI) therapy) [15] and general exclusion of malignancy-diagnosed patients in the clinical trials of currently approved COVID-19 vaccines [16]. Previous studies revealed that humoral and cell-mediated immunity to SARS-CoV-2 (COVID-19) are the integrated highly-effective-durable-protective key [17].

In conclusion, for continuation of the quality of oncological care, cancer patients on clinical trials should be prioritized for COVID-19 vaccination that do not affect the eligibility of the clinical trials.

### Bibliography

1. Bakouny Z., et al. "CD8+ T cells contribute to survival in patients with COVID-19 and cancer: current challenges and perspectives". *Cancer Cell* 38 (2020): 629-646.

2. Kuderer NM, *et al.* "Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study". *Lancet* 395 (2020): 1907-1918.
3. Mehta V, *et al.* "Case fatality rate of cancer patients with COVID-19 in a New York hospital system". *Cancer Discovery* 10 (2020): 935-941.
4. Grivas P, *et al.* "Association of clinical factors and recent anti-cancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium". *Annals of Oncology* 32 (2021): 787-800.
5. Robilotti EV, *et al.* "Determinants of COVID-19 disease severity in patients with cancer". *Nature Medicine* 26 (2020): 1218-1223.
6. Marra A, *et al.* "Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2". *Annals of Oncology* 32 (2020): 113-119.
7. Thakkar A, *et al.* "Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy". *Nature Cancer* 2 (2021): 392-399.
8. Chamilos G, *et al.* "Are all patients with cancer at heightened risk for severe coronavirus disease 2019 (COVID-19)?" *Clinical Infectious Disease* 72.2 (2021): 351-356.
9. Thakkar A, *et al.* "Seroconversion rates following COVID-19 vaccination among patients with cancer". *Cancer Cell* 39 (2021): 1-10.
10. Korompoki E, *et al.* "COVID-19 vaccines in patients with cancer-a welcome addition, but there is need for optimization". *JAMA Oncology* (2021): E1-E2.
11. Górecki DC and Simons JP. "The dangers of DNA vaccination". *Nature Medicine* 5.2 (1999): 126.
12. Kang CK, *et al.* "Cell-mediated immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors". *Journal of Infectious Disease* 222.11 (2020): 1902-1909.
13. Fanciullino R, *et al.* "COVID-19 vaccine race: watch your step for cancer patients". *British Journal of Cancer* 124.5 (2021): 860-861.
14. Desai A, *et al.* "COVID-19 vaccine guidance for patients with cancer participating in oncology Clinical Trials". *Nature Reviews Clinical Oncology* 18 (2021): 313-319.
15. Waissengrin B, *et al.* "Short-term safety on the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors". *Lancet Oncology* 22 (2021): 581-583.
16. Friese CR, *et al.* "Care without a compass: including patients with cancer in COVID-19 studies". *Cancer Cell* (2021).
17. Hwang JK, *et al.* "COVID-19 vaccines for patients with cancer : benefit likely outweigh risks". *Journal of Hematology and Oncology* 14 (2021): 38.

**Volume 4 Issue 10 October 2021**

**© All rights are reserved by Attapon Cheepsattayakorn, et al.**